Rating Rationale
July 10, 2019 | Mumbai
Medall Healthcare Private Limited
Ratings downgraded to 'CRISIL BBB+/Negative/CRISIL A2'
 
Rating Action
Total Bank Loan Facilities Rated Rs.218 Crore
Long Term Rating CRISIL BBB+/Negative (Downgraded from 'CRISIL A-/Negative')
Short Term Rating CRISIL A2 (Downgraded from 'CRISIL A2+')
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has downgraded its ratings on the bank facilities of Medall Healthcare Private Limited (MHPL; part of Medall group) to 'CRISIL BBB+/Negative/CRISIL A2' from 'CRISIL A-Negative/CRISIL A2+'.
 
The downgrade reflects CRISIL's belief that Medall group's financial risk profile is likely to remain constrained over the medium term driven by stretch in receivable collection. Receivable days of the group has increased to 120 days, as on March 31, 2019 as compared to 74 days, as on March 31, 2017 primarily on account of increase in receivable days with regards to its Public Private Partnership (PPP) business segment and franchise business in the private segment. Consequent to increase in working capital requirement, fund based working capital limits of MHPL have been utilized at an average of more than 90% over the twelve month period ended May 2019 and cash flow from operations have declined to less than Rs 15 crore in fiscal 2019 from over Rs 30 crore in fiscal 2017.
 
The ratings also reflect Medall group's established position in diagnostic industry and moderate financial risk profile. These strengths are partially offset by group's susceptibility to intense competition, vulnerability to technology risks and working capital intensive operations.

Analytical Approach

For arriving at the ratings, CRISIL has combined the business and financial risk profiles of MHPL and its subsidiaries, Clumax Diagnostics and Research Center Pvt Ltd and Medall Scans and Labs Pvt Ltd. The companies, collectively referred to as the Medall group, have significant business synergies.
 
Also, CRISIL has treated MHPL's compulsorily convertible preference shares of Rs 253.66 crore as equity.

Please refer Annexure - Details of consolidation, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers & Detailed Description
Strengths:
* Established regional market position in the diagnostic services industry: The Medall group is one of the top five service providers in the highly fragmented diagnostics services industry with a wide network of centres across South India. The group's revenues have grown at a compound annual growth rate of 15% over last five years through fiscal 2019.
 
* Moderate financial risk profile: The group's gearing is expected to remain lower than 0.75 times over the medium term despite debt funded capital expenditure (capex) of around Rs 35-40 crore owing to healthy profitability. Further, group's debt protection metrics is expected to remain comfortable with interest coverage ratio of more than 4 times and Net Cash Accruals to Total Debt (NCATD) ratio of more than 0.4 times over the medium term.
 
Weakness:
* Large working capital requirement: The group has large working capital requirement driven by its debtor days.  The group has significant portion of its receivables from Public Private Partnership (PPP) segment, on account of time lag in collection of receivables from government departments and corporates. The group also has receivables to the tune of around Rs 30 crore from the franchisees. Though the group has started taking steps in order to arrest further stretch in receivables in the private franchise business, the extent of improvement will be a key monitortable.
 
* Exposure to intense competition in the fragmented diagnostics services industry: The group faces intense competition from numerous players, including standalone diagnostic services as well as new hospitals with in-house diagnostic facilities.
 
* Vulnerability to technology risk: To stay ahead of the competition, diagnostics centres have to constantly upgrade technology. Upgrades not only involve significant capital investment but also increase maintenance costs, thereby increasing cost overhead.
Liquidity

Liquidity profile is marked by adequate cash accrual against debt repayment obligations, however, increase in receivable days resulting in increase in fund based working capital line utilization is a key constraining factor. The group is estimated to generate cash accrual to the tune of Rs 70-80 crore against repayment obligation of Rs 25 crore over the next two years. However, cash flow from operations had come down from Rs 33 crore in fiscal 2017 to around Rs 11 crore in fiscal 2019 owing to stretch in receivables. The bank lines of Rs 75 crore have been utilised at an average of more than 90% over last 12 months through May 2019.

Outlook: Negative

CRISIL believes the Medall group's credit risk profile is constrained on account of stretch in receivables. The ratings may be downgraded in case of further stretch in the group's receivables, thereby adversely impacting its liquidity. Conversely, the outlook may be revised to 'Stable' in case of improvement in group's working capital management while sustaining its revenue growth and profitability. 

About the Group

Medall was set up in 1994 as Precision Diagnostics Pvt Ltd, and got its present name after it was acquired by Mr Raju Venkataraman in 2009. Medall has two subsidiaries which also operate diagnostic centres.

Based in Chennai, Medall group operates diagnostic centres across South India, and in Maharashtra, Odisha and Jharkhand. In Andhra Pradesh, Telangana, and Jharkhand, the group operates through the PPP model also.

Key Financial Indicators
Particulars Unit 2018 2017 (&)
Net Revenue Rs crore 353.41 332.42
Profit after tax (PAT) Rs crore 27.80 (4.28)
PAT margin % 7.9 (1.3)
Adjusted debt/adjusted networth Times 0.60 0.70
Interest coverage Times 5.22 2.13
(&)Restated upon transition to Ind AS 

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of instrument Date of allotment Coupon
rate (%)
Maturity date Issue
size
(Rs cr)
Rating assigned with outlook
NA Bank Guarantee NA NA NA 5 CRISIL A2
NA Proposed Bank Guarantee NA NA NA 2 CRISIL A2
NA Proposed Long Term Bank Loan Facility NA NA NA 30 CRISIL BBB+/Negative
NA Proposed Short Term Bank Loan Facility NA NA NA 25 CRISIL A2
NA Cash Credit & Working Capital demand loan NA NA NA 75 CRISIL BBB+/Negative
NA Long Term Loan NA NA Dec 2025 81 CRISIL BBB+/Negative
 
Annexure - List of entities consolidated
Names of Entities Consolidated Extent of Consolidation Rationale for Consolidation
Clumax Diagnostics and Research Center Pvt Ltd   100% Wholly owned subsidiary
Medall Scans and Labs Pvt Ltd 100% Wholly owned subsidiary
Annexure - Rating History for last 3 Years
  Current 2019 (History) 2018  2017  2016  Start of 2016
Instrument Type Outstanding Amount Rating Date Rating Date Rating Date Rating Date Rating Rating
Fund-based Bank Facilities  LT/ST  211.00  CRISIL BBB+/Negative/ CRISIL A2  04-03-19  CRISIL A-/Negative/ CRISIL A2+  12-11-18  CRISIL A-/Negative/ CRISIL A2+  26-04-17  CRISIL A-/Stable/ CRISIL A2+  12-05-16  CRISIL BBB+/Positive/ CRISIL A2  CRISIL BBB+/Positive/ CRISIL A2 
            14-08-18  CRISIL A-/Watch Developing/ CRISIL A2+/Watch Developing  21-04-17  CRISIL A-/Stable/ CRISIL A2+       
Non Fund-based Bank Facilities  LT/ST  7.00  CRISIL A2  04-03-19  CRISIL A2+  12-11-18  CRISIL A2+  26-04-17  CRISIL A2+  12-05-16  CRISIL A2  CRISIL A2 
            14-08-18  CRISIL A2+/Watch Developing  21-04-17  CRISIL A2+       
All amounts are in Rs.Cr.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Bank Guarantee 5 CRISIL A2 Bank Guarantee 5 CRISIL A2+
Cash Credit & Working Capital demand loan 75 CRISIL BBB+/Negative Cash Credit & Working Capital demand loan 70 CRISIL A-/Negative
Long Term Loan 81 CRISIL BBB+/Negative Long Term Loan 81 CRISIL A-/Negative
Proposed Bank Guarantee 2 CRISIL A2 Proposed Bank Guarantee .3 CRISIL A2+
Proposed Long Term Bank Loan Facility 30 CRISIL BBB+/Negative Proposed Long Term Bank Loan Facility 40 CRISIL A-/Negative
Proposed Short Term Bank Loan Facility 25 CRISIL A2 Proposed Short Term Bank Loan Facility 21.7 CRISIL A2+
Total 218 -- Total 218 --
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
CRISILs Criteria for Consolidation
CRISILs Criteria for rating short term debt

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Vinay Rajani
Media Relations
CRISIL Limited
D: +91 22 3342 1835
M: +91 91 676 42913
B: +91 22 3342 3000
vinay.rajani@ext-crisil.com

Nitin Kansal
Director - CRISIL Ratings
CRISIL Limited
D:+91 124 672 2154
nitin.kansal@crisil.com


Sivasubramaniyan R T
Associate Director - CRISIL Ratings
CRISIL Limited
D:+91 44 6693 3633
Sivasubramaniyan.T@crisil.com


Padmaja Talatam
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 44 6656 3124
Padmaja.Talatam@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY
 
CRISIL respects your privacy. We may use your contact information, such as your name, address, and email id to fulfil your request and service your account and to provide you with additional information from CRISIL.For further information on CRISIL’s privacy policy please visit www.crisil.com.


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.CRISIL or its associates may have other commercial transactions with the company/entity.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL